Bär B M, de Witte T, de Pauw B E, Haanen C
Department of Internal Medicine, University Hospital, Nijmegen.
Neth J Med. 1990 Feb;36(1-2):19-24.
Seventeen consecutively admitted poor risk acute myeloid leukaemia (AML) patients and 4 patients with myelodysplastic syndrome (MDS) were treated with a remission-induction regimen consisting of a 7-day continuous intravenous infusion of conventional doses of cytarabine and of three 24-h constant rate infusions of daunorubicin administered intermittently on days 1, 3 and 5. The diagnoses were: relapsed primary AML in 6 patients, secondary AML in 11 patients (9 untreated, 2 relapsed) and MDS in 4 patients. The median age was 50 yr. Five of 6 patients with relapsed primary AML, 3 of 11 patients with secondary AML and 2 of 4 patients with MDS achieved complete remission (CR). The overall CR rate was 48% with a median remission duration of 5 months (range: 0.25-20 months). Few acute toxic side effects were observed thanks to the constant rate of infusion of daunorubicin.
17例连续收治的高危急性髓系白血病（AML）患者和4例骨髓增生异常综合征（MDS）患者接受了缓解诱导方案治疗，该方案包括连续7天静脉输注常规剂量阿糖胞苷，以及在第1、3和5天间歇给予三次24小时恒速输注柔红霉素。诊断结果为：6例原发性复发性AML，11例继发性AML（9例未经治疗，2例复发），4例MDS。中位年龄为50岁。6例原发性复发性AML患者中有5例、11例继发性AML患者中有3例以及4例MDS患者中有2例实现了完全缓解（CR）。总体CR率为48%，中位缓解持续时间为5个月（范围：0.25 - 20个月）。由于柔红霉素采用恒速输注，几乎未观察到急性毒副作用。
